Early Access — free while we kick the tires
EdgarHawk

DRMA Dermata Therapeutics, Inc. Insider Trading

Latest: SVP, Regulatory Affairs Bought $1,270 of Shares · Feb 2026
1 filing analyzed · Latest 2026-03-17
Insider buys
1
Insider sells
0
Unique insiders
1
Direction
Net buying
March 2026
2026-03-17
low
Bedoya-Toro Munera Maria E Buy
SVP, Regulatory Affairs
1,000 shares
$1,270
@ $1.27
Significance 4/10

SVP Bedoya-Toro purchases 1,000 shares of DRMA at $1.27; stock now -91.4% from 52-week high, company unprofitable.

Bedoya-Toro Munera Maria E, SVP of Regulatory Affairs, purchased 1,000 shares at $1.27, increasing her position from 12 shares to 1,012 shares. The transaction occurred at a significant discount to the 52-week high of $14.20; the stock currently trades at $1.22, having declined 47.0% over the past 90 days. The company posted a net loss of $-1.7M with a market capitalization of only $1.3M, indicating a distressed financial position. While the insider's position increased 8333.3% in percentage terms, the absolute dollar value of the purchase ($1.3K) is modest and the company's deep unprofitability limits the significance of a mid-level executive's small open-market buy.

Get alerts for DRMA

Add DRMA to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access